Journal of Leukemia
Open Access

Treatment of Pediatric Leukemia and its Symptoms

Semsei Agnes^{* *}Correspondence: Semsei Agnes, Department of Leukemia, University of Debrecen, Debrecen, Hungary, Email:

Author info »

Description

Pediatric leukemia, also known as childhood leukemia, is a type of cancer that affects the blood and bone marrow. Leukemia is the most common cancer in children, comprising about 30% of all childhood cancers. It originates in the bone marrow, where blood cells are produced, and involves the abnormal overproduction of immature white blood cells, which crowd out normal blood cells. Leukemia in children is classified into several types, with the two main categories being Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). These subtypes differ in terms of the specific blood cells affected and how they behave. Acute Lymphoblastic Leukemia (ALL) is the most common type of leukemia in children, accounting for approximately 75%-80% of cases. ALL originates in the lymphoid cells, which are responsible for producing white blood cells called lymphocytes. In ALL, immature lymphoid cells, known as lymphoblasts, proliferate uncontrollably, interfering with the production of normal blood cells. The exact cause of ALL is not fully understood, but certain genetic and environmental factors may play a role. Risk factors for ALL include exposure to radiation, certain genetic disorders such as Down syndrome, and certain viral infections. Symptoms of ALL may vary but often include fatigue, weakness, pale skin, fever, frequent infections, easy bruising or bleeding, bone pain, and swollen lymph nodes. Children with ALL may also experience loss of appetite, weight loss, and abdominal pain. Diagnosis of ALL typically involves a combination of blood tests, bone marrow aspiration and biopsy, and imaging tests such as X-rays, CT scans, or MRI scans. A lumbar puncture may also be performed to evaluate whether leukemia cells have spread to the central nervous system.

Treatment for ALL in children usually consists of chemotherapy, which may be administered orally, intravenously, or intrathecal (into the spinal fluid). Depending on the subtype and risk factors, additional treatments such as radiation therapy, targeted therapy, and stem cell transplantation may be recommended. The overall prognosis for children with ALL has improved significantly over the past few decades, with cure rates exceeding 90% in many cases. Acute Myeloid Leukemia (AML) is less common in children than ALL, accounting for about 15%-20% of childhood leukemia cases. AML originates in the myeloid cells, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets. In AML, immature myeloid cells, known as myoblasts, proliferate rapidly and interfere with normal blood cell production. The exact cause of AML in children is not well understood, although certain genetic syndromes and exposure to chemotherapy or radiation therapy for previous cancers may increase the risk. Symptoms of AML in children are similar to those of ALL and may include fatigue, weakness, fever, frequent infections, easy bruising or bleeding, bone pain, and swollen lymph nodes.

Diagnosis of AML involves similar procedures as ALL, including blood tests, bone marrow aspiration and biopsy, and imaging tests. A lumbar puncture may also be performed to assess whether leukemia cells have spread to the central nervous system. Treatment for AML in children typically involves chemotherapy, often administered in multiple cycles. Some children may require stem cell transplantation, especially those with high-risk disease or those who do not achieve remission with chemotherapy alone. Targeted therapies and novel treatment approaches are also being investigated in clinical trials to improve outcomes for children with AML. Treating pediatric leukemia poses unique challenges due to the young age and developing bodies of affected children. Chemotherapy and other cancer treatments can have significant side effects, including nausea, vomiting, hair loss, and increased susceptibility to infections. Long-term complications such as infertility, growth delays, and secondary cancers are also concerns for childhood leukemia survivors.

Furthermore, psychosocial support for children and their families is essential throughout the treatment process. Coping with a cancer diagnosis, prolonged hospital stays, and the uncertainty of outcomes can take a toll on both children and their caregivers. Pediatric oncology teams often include child life specialists, social workers, and psychologists who provide emotional support and help families navigate the challenges of cancer treatment. Advances in understanding the biology of leukemia and the development of targeted therapies have led to significant improvements in the treatment of pediatric leukemia in recent years. Clinical trials are ongoing to evaluate new treatment approaches, including immunotherapy, precision medicine, and novel drug combinations. Additionally, efforts are underway to identify biomarkers and genetic mutations that may help predict treatment response and guide personalized therapy for children with leukemia. Collaborative research initiatives involving pediatric oncologists, researchers, and advocacy groups aim to accelerate progress in the field and improve outcomes for children with leukemia.

Conclusion

Pediatric leukemia remains a significant health concern, but advancements in diagnosis and treatment have transformed the prognosis for affected children. With multimodal treatment approaches, including chemotherapy, radiation therapy, targeted therapy, and stem cell transplantation, the majority of children with leukemia can achieve remission and long-term survival. Ongoing research efforts and collaborative initiatives hold promise for further improving outcomes and quality of life for children battling this disease.